<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752856</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 589</org_study_id>
    <nct_id>NCT00752856</nct_id>
  </id_info>
  <brief_title>Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients</brief_title>
  <official_title>Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCTG 589 is a randomized, open-label, pilot study comparing the efficacy, safety and
      tolerability of RAL plus LPV/r to EFV plus TDF/FTC in HIV-infected, treatment-naïve subjects.
      Subjects will be ineligible if they have any evidence of drug resistant virus in the past or
      at the time of screening (if never previously tested). Those who are found to be eligible
      will be randomized 1:1 to initiate either LPV/r (400/100 mg) plus RAL (400mg), both given
      twice-daily, or fixed dose combination of EFV (600 mg), TDF (300 mg) and FTC (200 mg) given
      as once-daily Atripla® for 48 weeks.

      Hypotheses

        1. The novel nucleoside-sparing combination of LPV/r + RAL will have a faster phase 1 viral
           decay rate compared to standard-of-care therapy with EFV/TDF/FTC in antiretroviral-naïve
           patients.

             1. Faster phase 1 viral decay dynamics will be associated with improved longer-term
                (week 48) viral suppression.

             2. Faster phase 1 viral decay dynamics will be associated with accelerated early (Day
                0-14) clearance of cell-associated HIV DNA.

             3. Faster phase 1 viral decay dynamics will be associated with greater early (baseline
                to week 12) CD4+ T-cell recovery.

        2. The LPV/r + RAL arm will have greater decreases in early (baseline to week 4) CD4/CD8
           T-cell immune activation and apoptosis which will be associated with greater late (week
           12 to week 48) CD4+ T-cell recovery.

        3. Subjects treated with LPV/r + RAL arm will have smaller changes in total cholesterol and
           triglycerides from baseline than those receiving EFV/TDF/FTC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine how well a new anti-HIV drug combination (RAL plus
      LPV/r) taken twice a day decreases the amount of HIV found in participants' blood (viral
      load) compared to taking the once-a-day combination pill Atripla®. This study will also try
      to determine if the new combination has fewer side effects and is tolerated better than
      Atripla®. Another reason this study is being done is to see if this new drug combination
      helps participants' body's CD4 cells recover differently and will also look at how well
      participants' bodies absorbs these drugs and how safe these drugs are when given together.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2008</start_date>
  <completion_date type="Actual">February 11, 2014</completion_date>
  <primary_completion_date type="Actual">May 5, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.</measure>
    <time_frame>Baseline, days 2, 7, 10, 14</time_frame>
    <description>Repeated HIV RNA measured at different time points (baseline, days 2, 7, 10, 14) will be treated as the outcome variable in a linear mixed-effects model. The primary fixed effects will include time, treatment group, treatment group-by-time interaction; random effects will include both intercept and slope allowing each subject to have individual baseline viral load and viral decay (rate of decrease in viral load following initiation of antiretroviral therapy). The treatment group-by- time interaction term in the model will indicate the difference in viral decay rates between the two treatment groups. Baseline covariate adjustment will be included if necessary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Suppression Efficacy at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>To determine the antiviral efficacy of LPV/r + RAL compared to EFV/TDF/FTC after 48 weeks of treatment by achieving undetectable viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>To compare early (baseline to Week 4) activated CD4+ T-cell recovery rates between treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>To compare late (baseline to Week 48) activated CD4+ T-cell recovery rates between treatment regimens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1 - Kaletra + Isentress taken twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Atripla taken once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kaletra + Isentress</intervention_name>
    <description>kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
    <arm_group_label>1 - Kaletra + Isentress taken twice daily</arm_group_label>
    <other_name>Lopinavir/ritonavir (LPV/r) + Raltegravir (RAL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atripla</intervention_name>
    <description>Atripla 1 tab once a day</description>
    <arm_group_label>2 - Atripla taken once daily</arm_group_label>
    <other_name>Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection.

          -  Treatment naïve (defined as having never received any HIV antiretroviral agents in
             past).

          -  CD4+ T-cell count greater than or equal to 50 cells/mm3

          -  HIV viral load greater than or equal to 5,000 copies/mL

          -  Laboratory values obtained by screening laboratories within 30 days of entry:

               -  Absolute neutrophil count (ANC) greater than 750/mm3.

               -  Hemoglobin greater than 8.0 g/dL.

               -  Platelet count greater than 50,000/mm3.

               -  Calculated creatinine clearance (CrCl) &gt; 60 mL/min as estimated by the
                  Cockcroft-Gault equation:

                    -  For men, (140 - age in years) x (body weight in kg) ÷ (serum creatinine in
                       mg/dL x 72) = CrCl (mL/min)

                    -  For women, multiply the result by 0.85 = CrCl (mL/min)

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase less than 5 x ULN.

               -  Total bilirubin less than 2.5 x ULN.

          -  Females of childbearing potential must have a negative serum pregnancy test at
             screening and agree to use a double-barrier method of contraception throughout the
             study period.

          -  Men and women age greater than or equal to 18 years.

          -  Ability to obtain prescription for HIV antiretroviral medications and to have required
             prescriptions filled prior to entry.

          -  Ability and willingness of subject to give written informed consent

        Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Serious illness requiring systemic treatment and/or hospitalization until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigator, for at least 30 days prior to study entry (day 0).

          -  Acute therapy for serious infection or other serious medical illnesses (in the
             judgment of the site investigator) requiring systemic treatment and/or hospitalization
             within 14 days prior to study entry (day 0).

          -  Evidence of HIV seroconversion within 6 months prior to study entry.

          -  Evidence of any major HIV drug resistance-associated mutation on any genotype
             performed prior to study entry or at the time of screening.

          -  History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA
             detectable).

          -  History of chronic active hepatitis B (defined as surface antigen positive and/or HBV
             DNA detectable).

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of
             study entry.

          -  Use of human growth hormone within 30 days prior to study entry.

          -  Initiation of testosterone or anabolic steroids within 30 days prior to study entry.
             (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is
             allowed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Haubrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Collaborative Treatment Group (CCTG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UC San Diego AntiViral Research Center (AVRC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Living Hope Clinical Foundation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisity California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert AIDS Project</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 13, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>June 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sheldon Morris</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>HIV treatment</keyword>
  <keyword>Treatment-naive</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT00752856/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 - Kaletra + Isentress Taken Twice Daily</title>
          <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
        </group>
        <group group_id="P2">
          <title>2 - Atripla Taken Once Daily</title>
          <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>randomized but did not do viral kinetics</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - Kaletra + Isentress Taken Twice Daily</title>
          <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
        </group>
        <group group_id="B2">
          <title>2 - Atripla Taken Once Daily</title>
          <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="30.3" upper_limit="47.5"/>
                    <measurement group_id="B2" value="43" lower_limit="32.7" upper_limit="47.8"/>
                    <measurement group_id="B3" value="43" lower_limit="31" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.</title>
        <description>Repeated HIV RNA measured at different time points (baseline, days 2, 7, 10, 14) will be treated as the outcome variable in a linear mixed-effects model. The primary fixed effects will include time, treatment group, treatment group-by-time interaction; random effects will include both intercept and slope allowing each subject to have individual baseline viral load and viral decay (rate of decrease in viral load following initiation of antiretroviral therapy). The treatment group-by- time interaction term in the model will indicate the difference in viral decay rates between the two treatment groups. Baseline covariate adjustment will be included if necessary.</description>
        <time_frame>Baseline, days 2, 7, 10, 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Kaletra + Isentress Taken Twice Daily</title>
            <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
          </group>
          <group group_id="O2">
            <title>2 - Atripla Taken Once Daily</title>
            <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.</title>
          <description>Repeated HIV RNA measured at different time points (baseline, days 2, 7, 10, 14) will be treated as the outcome variable in a linear mixed-effects model. The primary fixed effects will include time, treatment group, treatment group-by-time interaction; random effects will include both intercept and slope allowing each subject to have individual baseline viral load and viral decay (rate of decrease in viral load following initiation of antiretroviral therapy). The treatment group-by- time interaction term in the model will indicate the difference in viral decay rates between the two treatment groups. Baseline covariate adjustment will be included if necessary.</description>
          <units>log(10)/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.42" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.52" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Suppression Efficacy at 48 Weeks</title>
        <description>To determine the antiviral efficacy of LPV/r + RAL compared to EFV/TDF/FTC after 48 weeks of treatment by achieving undetectable viral load</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Kaletra + Isentress Taken Twice Daily</title>
            <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
          </group>
          <group group_id="O2">
            <title>2 - Atripla Taken Once Daily</title>
            <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Suppression Efficacy at 48 Weeks</title>
          <description>To determine the antiviral efficacy of LPV/r + RAL compared to EFV/TDF/FTC after 48 weeks of treatment by achieving undetectable viral load</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.</title>
        <description>To compare early (baseline to Week 4) activated CD4+ T-cell recovery rates between treatment regimens.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Participants who achieved viral suppression at week 24 and maintained it at week 48 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Kaletra + Isentress Taken Twice Daily</title>
            <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
          </group>
          <group group_id="O2">
            <title>2 - Atripla Taken Once Daily</title>
            <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.</title>
          <description>To compare early (baseline to Week 4) activated CD4+ T-cell recovery rates between treatment regimens.</description>
          <population>Participants who achieved viral suppression at week 24 and maintained it at week 48 were included in this analysis.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" lower_limit="-6.12" upper_limit="-1.51"/>
                    <measurement group_id="O2" value="-1.18" lower_limit="-3.17" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48</title>
        <description>To compare late (baseline to Week 48) activated CD4+ T-cell recovery rates between treatment regimens.</description>
        <time_frame>48 weeks</time_frame>
        <population>Participants who achieved viral suppression at week 24 and maintained it at week 48 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Kaletra + Isentress Taken Twice Daily</title>
            <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
          </group>
          <group group_id="O2">
            <title>2 - Atripla Taken Once Daily</title>
            <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48</title>
          <description>To compare late (baseline to Week 48) activated CD4+ T-cell recovery rates between treatment regimens.</description>
          <population>Participants who achieved viral suppression at week 24 and maintained it at week 48 were included in this analysis.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" lower_limit="-5.83" upper_limit="1.36"/>
                    <measurement group_id="O2" value="-5.65" lower_limit="-8.76" upper_limit="-2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 - Kaletra + Isentress Taken Twice Daily</title>
          <description>Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
Kaletra + Isentress: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day</description>
        </group>
        <group group_id="E2">
          <title>2 - Atripla Taken Once Daily</title>
          <description>Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
Atripla: Atripla 1 tab once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Symptoms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Aches &amp; Muscle Discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any CNS Symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheldon Morris</name_or_title>
      <organization>UCSD</organization>
      <phone>8583364088</phone>
      <email>shmorris@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

